Day One Biopharmaceuticals, Inc. (DAWN) Insider Trading

Last 12 months

Insiders sold $672k and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Head of Research and Dev. Michael Vasconcelles sold $32k on Feb 17, 38% of their stake, outside a plan. The last open-market buy by an executive or director was in Jun 2022.

Net open-market

−$672k

0 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Jun 2022

Jun 17, 2022

Get an email when DAWN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Feb 17	Jeremy Bender CHIEF EXECUTIVE OFFICER	SoldNo plan	15,459	$11.60	$179k	6.4%	Form 4
Feb 17	Lauren Merendino Chief Commercial Officer	SoldNo plan	5,814	$11.60	$67k	8.8%	Form 4
Feb 17	Adam Dubow Gen Counsel & Secretary	SoldNo plan	6,395	$11.60	$74k	8.1%	Form 4
Feb 17	Michael Vasconcelles Head of Research and Dev.	SoldNo plan	2,728	$11.60	$32k	38%	Form 4
Feb 17	Charles N York II COO and CFO	SoldNo plan	6,065	$11.60	$70k	1.9%	Form 4
Nov 17, 2025	Jeremy Bender CHIEF EXECUTIVE OFFICER	SoldNo plan	15,894	$8.91	$142k	4.7%	Form 4
Nov 17, 2025	Lauren Merendino Chief Commercial Officer	SoldNo plan	3,726	$8.91	$33k	6.8%	Form 4
Nov 17, 2025	Adam Dubow Gen Counsel & Secretary	SoldNo plan	4,319	$8.91	$38k	6.5%	Form 4
Nov 17, 2025	Charles N York II COO and CFO	SoldNo plan	4,062	$8.91	$36k	1.4%	Form 4
Aug 18, 2025	Charles N York II COO and CFO	SoldNo plan	4,106	$6.77	$28k	1.5%	Form 4
Aug 18, 2025	Adam Dubow Gen Counsel & Secretary	SoldNo plan	4,365	$6.77	$30k	7.4%	Form 4
Aug 18, 2025	Jeremy Bender CHIEF EXECUTIVE OFFICER	SoldNo plan	16,058	$6.77	$109k	1.0%	Form 4
Aug 18, 2025	Lauren Merendino Chief Commercial Officer	SoldNo plan	3,766	$6.77	$25k	8.2%	Form 4
May 16, 2025	Lauren Merendino Chief Commercial Officer	SoldNo plan	3,927	$6.26	$25k	10%	Form 4
May 16, 2025	Adam Dubow GENERAL COUNSEL	SoldNo plan	4,552	$6.26	$28k	8.8%	Form 4
May 16, 2025	Charles N York II COO, CFO AND SECRETARY	SoldNo plan	4,282	$6.26	$27k	1.6%	Form 4
May 16, 2025	Jeremy Bender CHIEF EXECUTIVE OFFICER	SoldNo plan	13,964	$6.26	$87k	4.3%	Form 4
Feb 18, 2025	Charles N York II COO, CFO AND SECRETARY	SoldNo plan	4,370	$11.96	$52k	1.7%	Form 4
Feb 18, 2025	Adam Dubow GENERAL COUNSEL	SoldNo plan	4,646	$11.96	$56k	10%	Form 4
Feb 18, 2025	Jeremy Bender CHIEF EXECUTIVE OFFICER	SoldNo plan	12,048	$11.96	$144k	1.3%	Form 4
Dec 10, 2024	Samuel C. Blackman HEAD OF R&D	Sold10b5-1 plan	30,000	$13.31	$399k	1.5%	Form 4
Nov 18, 2024	Jeremy Bender CHIEF EXECUTIVE OFFICER	SoldNo plan	10,554	$13.21	$139k	3.3%	Form 4
Nov 18, 2024	Samuel C. Blackman HEAD OF R&D	SoldNo plan	2,206	$13.21	$29k	0.1%	Form 4
Nov 18, 2024	Adam Dubow GENERAL COUNSEL	SoldNo plan	3,165	$13.21	$42k	9.0%	Form 4
Nov 18, 2024	Charles N York II COO, CFO AND SECRETARY	SoldNo plan	2,602	$13.21	$34k	1.1%	Form 4
Nov 8, 2024 – Nov 11, 2024	Samuel C. Blackman HEAD OF R&D	Sold10b5-1 plan 2 parts	28,255	$16.15 average	$456k	1.4%	Form 4
Nov 7, 2024	Samuel C. Blackman HEAD OF R&D	Sold10b5-1 plan	11,245	$16.03	$180k	0.5%	Form 4
Oct 31, 2024	Samuel C. Blackman HEAD OF R&D	Sold10b5-1 plan	500	$16.02	$8k	<0.1%	Form 4

Feb 17No plan
Jeremy Bender
CHIEF EXECUTIVE OFFICER · sold 15,459 at $11.60
$179k
6.4% of stake
Feb 17No plan
Lauren Merendino
Chief Commercial Officer · sold 5,814 at $11.60
$67k
8.8% of stake
Feb 17No plan
Adam Dubow
Gen Counsel & Secretary · sold 6,395 at $11.60
$74k
8.1% of stake
Feb 17No plan
Michael Vasconcelles
Head of Research and Dev. · sold 2,728 at $11.60
$32k
38% of stake
Feb 17No plan
Charles N York II
COO and CFO · sold 6,065 at $11.60
$70k
1.9% of stake
Nov 17, 2025No plan
Jeremy Bender
CHIEF EXECUTIVE OFFICER · sold 15,894 at $8.91
$142k
4.7% of stake
Nov 17, 2025No plan
Lauren Merendino
Chief Commercial Officer · sold 3,726 at $8.91
$33k
6.8% of stake
Nov 17, 2025No plan
Adam Dubow
Gen Counsel & Secretary · sold 4,319 at $8.91
$38k
6.5% of stake
Nov 17, 2025No plan
Charles N York II
COO and CFO · sold 4,062 at $8.91
$36k
1.4% of stake
Aug 18, 2025No plan
Charles N York II
COO and CFO · sold 4,106 at $6.77
$28k
1.5% of stake
Aug 18, 2025No plan
Adam Dubow
Gen Counsel & Secretary · sold 4,365 at $6.77
$30k
7.4% of stake
Aug 18, 2025No plan
Jeremy Bender
CHIEF EXECUTIVE OFFICER · sold 16,058 at $6.77
$109k
1.0% of stake
Aug 18, 2025No plan
Lauren Merendino
Chief Commercial Officer · sold 3,766 at $6.77
$25k
8.2% of stake
May 16, 2025No plan
Lauren Merendino
Chief Commercial Officer · sold 3,927 at $6.26
$25k
10% of stake
May 16, 2025No plan
Adam Dubow
GENERAL COUNSEL · sold 4,552 at $6.26
$28k
8.8% of stake
May 16, 2025No plan
Charles N York II
COO, CFO AND SECRETARY · sold 4,282 at $6.26
$27k
1.6% of stake
May 16, 2025No plan
Jeremy Bender
CHIEF EXECUTIVE OFFICER · sold 13,964 at $6.26
$87k
4.3% of stake
Feb 18, 2025No plan
Charles N York II
COO, CFO AND SECRETARY · sold 4,370 at $11.96
$52k
1.7% of stake
Feb 18, 2025No plan
Adam Dubow
GENERAL COUNSEL · sold 4,646 at $11.96
$56k
10% of stake
Feb 18, 2025No plan
Jeremy Bender
CHIEF EXECUTIVE OFFICER · sold 12,048 at $11.96
$144k
1.3% of stake
Dec 10, 202410b5-1 plan
Samuel C. Blackman
HEAD OF R&D · sold 30,000 at $13.31
$399k
1.5% of stake
Nov 18, 2024No plan
Jeremy Bender
CHIEF EXECUTIVE OFFICER · sold 10,554 at $13.21
$139k
3.3% of stake
Nov 18, 2024No plan
Samuel C. Blackman
HEAD OF R&D · sold 2,206 at $13.21
$29k
0.1% of stake
Nov 18, 2024No plan
Adam Dubow
GENERAL COUNSEL · sold 3,165 at $13.21
$42k
9.0% of stake
Nov 18, 2024No plan
Charles N York II
COO, CFO AND SECRETARY · sold 2,602 at $13.21
$34k
1.1% of stake
Nov 8, 2024 – Nov 11, 202410b5-1 plan
Samuel C. Blackman
HEAD OF R&D · sold 28,255 at avg $16.15
$456k
1.4% of stake
Nov 7, 202410b5-1 plan
Samuel C. Blackman
HEAD OF R&D · sold 11,245 at $16.03
$180k
0.5% of stake
Oct 31, 202410b5-1 plan
Samuel C. Blackman
HEAD OF R&D · sold 500 at $16.02
$8k
<0.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DAWN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

HRTXHeron Therapeutics Inc.

KPTIKaryopharm Therapeutics Inc.

NUVBNuvation Bio Inc.

ELTPElite Pharmaceuticals Inc.

ZVRAZevra Therapeutics, Inc.

ABUSArbutus Biopharma Corporation

LFVNLifeVantage Corporation

MGNXMacrogenics Inc.

Spot a number that looks wrong? Check it in DAWN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DAWN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.